Milestone Pharmaceuticals Inc. Depreciation
Milestone Pharmaceuticals Inc. (MIST) reported Depreciation of $114.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-20
- Milestone Pharmaceuticals Inc. depreciation for fiscal 2025 was $114.00K, a 8.57% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. depreciation for fiscal 2024 was $105.00K, a 14.13% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. depreciation for fiscal 2023 was $92.00K, a 3.37% increase from fiscal 2022.
- Milestone Pharmaceuticals Inc. depreciation for fiscal 2022 was $89.00K.
| Period end | Depreciation 12 month |
|---|---|
| 2025-12-31 | $114.00K 10-K · filed 2026-03-20 |
| 2024-12-31 | $105.00K 10-K · filed 2026-03-20 |
| 2023-12-31 | $92.00K 10-K · filed 2025-03-13 |
| 2022-12-31 | $89.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |